Bettersize’s upcoming webinar will delve into particle size and zeta potential, showcasing their importance in pharmaceutical development and product quality.
Subclinical Afib Caught on Cardiac Devices Might Be Better Left Alone
AMSTERDAM — Edoxaban (Savaysa) didn’t improve outcomes for high-risk patients with subclinical atrial fibrillation (Afib)-like episodes detected by implanted cardiac devices, the NOAH-AFNET 6 trial